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Abstract
Background: The World Health Organisation approved boosted atazanavir as a preferred second line protease
inhibitor in 2010. This is as an alternative to the current boosted lopinavir. Atazanavir has a lower genetic barrier
than lopinavir. We compared the virological outcomes of patients during the roll out of routine viral load
monitoring, who had switched to boosted second- line regimens of either atazanavir or lopinavir.
Methods: This was a cross-sectional study involving adult patients at the Infectious Diseases Institute Kampala,
Uganda started on a standard WHO recommended second-line regimen containing either boosted atazanavir or
boosted lopinavir between 1 Dec 2014 and 31 July 2015.. Mantel -Haenszel chi square was used to test for the
statistical significance of the odds of being suppressed (VL < 400 copies/ml) when on boosted atazanavir compared
to boosted lopinavir after stratifying by duration on antiretroviral therapy (ART). Multivariate logistic regression
analysis used to determine if the type of boosted protease inhibitor (bPI) was associated with virological outcome.
Results: Ninety (90) % on ATV/r and 83% on LPV/r had a VL less than 1000 copies/ml. The odds of being
suppressed using the same viral load cut-off while on boosted atazanavir compared to boosted lopinavir was not
statistically significant after stratifying for duration on ART (p = 0.09). In a multivariate analysis the type of bPI used
was not a predictor of virological outcome (p = 0.60).
Conclusions: Patients using the WHO recommended second-line of boosted atazanavir have comparable
virological suppression to those on boosted lopinavir.
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Background
The Joint United Nations Programme on HIV and AIDS
(UNAIDS) 2016 report estimates that 17 million people
living with HIV are accessing antiretroviral therapy
(ART), 60.6% (10.3 million) of these are living in
sub-Saharan Africa [1]. Employing a public health
approach to HIV treatment with a simplified and stan-
dardized package of care has allowed a large number of
patients to access lifesaving ART in highly under
-resourced settings [2]. This public health approach rec-
ommends first-line regimens that are replaced by
second-line regimens when treatment failure to the
first-line regimen occurs.
Prior to 2013, treatment failure was determined using
clinical criteria (e.g. new or recurrent World Health Or-
ganisation stage 4 opportunistic infections) or immuno-
logical criteria (dropping CD4 count or persistent < 100
cells/ml) or a detectable viral load (VL) greater than
5000 copies/ml. Since 2013, routine viral load monitor-
ing has been recommended for monitoring response to
ART. While the exact number of patients on second-line
therapy in resource limited settings is not known, the
World Health Organisation (WHO) estimates that 6% of
all individuals receiving first-line therapy in sub-Saharan
Africa need to switch to second-line regimens in any
given year [3]. However, a meta-analysis by Yoann
Madec et al. estimated that only 3% of the patients on
ART in resource limited settings (RLS) receive second-
line ART [4].
The recommended first-line regimen by WHO for a
public health approach consists of two nucleos(t)ides
reverse transcriptase inhibitors (NRTIs, preferred is
tenofovir disproxil fumarate) and a non-nucleoside
reverse transcriptase inhibitor (NNRTI, preferred is efa-
virenz 600mg). The second-line regimen comprises of
two nucleosides reverse transcriptase inhibitors (NRTIs)
plus a boosted protease inhibitor (bPI) (preferred is
boosted lopinavir or boosted atazanavir) [5–7]. Due to
the lack of resistance testing, patients who fail first-line
therapy are at risk of multiple mutations to their
nucleos(t)ide reverse transcriptase inhibitors (NRTIs)
and yet these are recycled in the second-line [5, 8–11].
It is known that bPIs have a high genetic barrier to
resistance, therefore it is recommended that they be
used alongside NRTIs to enhance efficacy of the regi-
men [12–14].
Guidelines initially recommended boosted lopinavir
as the preferred protease inhibitor, but in 2010 the
WHO revision of guidelines for ART for HIV in
adults and adolescents added boosted atazanavir
alongside boosted lopinavir as preferred bPIs for
second-line therapy [14–16]. Whilst first-line boosted
atazanavir and boosted lopinavir based regimens have
been compared and proven to be equally efficacious
in patients starting first-line, there are no randomized
controlled trials or large observational studies that
have compared the efficacy of the two drug regimens
ATV/r and LPV/r in resource limited settings that
follow the WHO policy with probable late diagnosis
of first-line ART failure [17–19]. Further evidence for
the recommendations for these drugs are based
mainly on studies in resource rich settings with access
to resistance testing to determine the most efficacious
second-line regimens [18].
In 2011, Uganda adopted the WHO recommendation
to use boosted atazanavir as a preferred alternative to
boosted lopinavir [20]. The reasons for the preferential
use are; the one tablet once daily dosing of boosted ata-
zanavir and its better lipid and gastrointestinal
side-effect profile. Prior to December 2014, VL testing
was not performed for routine ART monitoring. In
2014, routine VL monitoring for all patients was rolled
out in Uganda and this presented an opportunity to
determine the outcomes of patients switched to boosted
atazanavir and boosted lopinavir based regimens. We
undertook a cross-sectional study of all people receiving
standard second-line treatment during the roll out of
routine VL monitoring between 1 Dec 2014 and 31 July
2015 at the Infectious Diseases Institute. This study
aimed to describe the virological outcomes of patients
who were on boosted second-line regimen of either ata-
zanavir or lopinavir at that time.
Methods
The Infectious Diseases Institute (IDI) in Kampala,
Uganda is a center for specialist management of HIV
with over 8000 patients in care, and 1200 of these were
on second-line therapy. Patient medical records are
maintained via an electronic system and use of all rou-
tinely collected clinic data is approved for analysis and
reporting by the Makerere University Faculty of Medi-
cine, Research and Ethics committee (approval number:
120–2009) and Uganda National Council for Science
and Technology (approval number: 45683) hence the
need for consent was waived by an IRB. All abstracted
data was de-identified and stored on a password pro-
tected computer to protect maintain patients’ anonym-
ity. We identified patients who were initiated on a
second-line therapy of boosted atazanavir and boosted
lopinavir between 01/Jan/2010 and 01/Dec/2014. We in-
cluded patients aged ≥18 years, who were active
(attended clinic at least once in the previous 3months),
had undergone VL testing and who had been on a stand-
ard first-line therapy comprising of two NRTIS and
either nevirapine (NVP) or efavirenz (EFV) and switched
to a standard second-line of two NRTIs (one new and
the other recycled) and either boosted atazanavir or
boosted lopinavir. These drugs are generic preparations,
Laker et al. BMC Infectious Diseases          (2019) 19:280 Page 2 of 7
from WHO accredited manufacturers. All reviewed
patients must have attended clinic at least once in the
previous 3 months (not lost to follow up) and must have
been on second-line therapy for at least 6 months.
Patients who missed their routine visits in the study
period were excluded as well as those who were enrolled
in an ongoing observational cohort and were being
followed up using non-routine VLs.
From December 2014, routine VLs were carried out at
the Ministry of Health Central Public Health Laboratory
(CPHL) using (Roche CAP-CTM and Abbott M2000sp/
M2000rt with cut-offs of 20 copies/μL and 75 copies/ μL
respectively). Results were returned back to the facility
within 2 weeks.
Baseline demographic and clinical characteristics at
the time of switch to second-line were compared
between patients on boosted atazanavir and boosted
lopinavir Categorical variables were compared using the
chi-square test. The Wilcoxon rank-sum test was used
to compare non-normally distributed continuous vari-
ables. Virological suppression was defined as having a
VL less than 400 copies/ml.
Mantel -Haenszel chi square was used to test for the
statistical significance of the odds of being suppressed
when on boosted atazanavir compared to boosted lopi-
navir after stratifying by duration on ART. Propensity
scores were generated to account for the probability of
being switched to either boosted atazanavir or boosted
lopinavir and the variables used to predict this were type
of type of bPI, gender, age, body mass index (BMI) and
CD4 at switch to second-line. At the multivariable level
analysis, a logistic regression was used to determine the
factors associated with suppression (VL < 400 copies/
ml)., Only variables with an unadjusted P value less than
0.2.. Variables were considered significant at the 95%
level.
Results
A total of 285 patients had ever been started on boosted
atazanavir (ATV/r) and 271 on boosted lopinavir (LPV/
r) in the study period, of which 252 (88.4%) and 225
(83.0%) were still active in the clinic and 224 in the
ATV/r, and 205 in the LPV/r had a VL available. The
rates of loss to follow up, death and transfer outs of pa-
tients started on ATV/r and on LPV/r were similar;(33/
285) 12% on ATV/r and (46/271) 17% on LPV/r (p =
0.315) (Fig. 1).
The majority in either group were female (ATV/r: 148
(66.1%), LPV/r: 128 (62.4%), the median age (IQR) was
37 (30–42) and 36 years (31–42) respectively for ATV/r
and LPV/r. Most patients at time of switch had a normal
BMI, low CD4 below 200 cells/mm3 and had been on
nevirapine with no difference between the groups (Table
1). The median log VL in both groups at time of switch
was high 4.5 (3.8–4.9) and 4.5 (3.2–5.1) respectively for
ATV/r and LPV/r and not statistically different. Patients
Fig. 1 Follow up status of patients ever started on boosted atazanavir and on boosted lopinavir at time of study
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on ATV/r had been on a first-line treatment for a longer
duration with a median of 56 months (28–80) as com-
pared to 46months (25–67) for patients on LPV/r (p =
0.025). The median duration (IQR) on second-line by
time of VL was also shorter for patients on (ATV/r)19
months (21–25) versus 40 months on LPV/r (32–52) (p
< 0.001)). TDF/3TC was the NRTI combination used in
the majority, mostly in the group on ATV/r (85.3%)
compared to 154 (75.1%) on LPV/r (P < 0.05) .
90% on ATV/r and 83% on LPV/r had a VL < 400 cop-
ies /ml. However, after stratifying by time on second-line
therapy this was not statistically significant (p = 0.09).
Further sensitivity analyses using a cut-off of VL < 1000
copes/ ml resulted in 92% on ATV/r and 85% on LP/r
suppressed and after stratifying by time on second-line
therapy this was also not statistically significant. (p =
0.26). However, a cut-off of < 75 copies/ml showed that
the odds of being suppressed were more favorable for
ATV/r (85%) compared to LPV/r (76%) on stratifying by
time on therapy (p = 0.03) (Fig. 2).
In a multivariate analysis controlling for the effects of
sex, age at switch to second-line ART, CD4 at switch,
time on first-line therapy and time from switch to
second-line to VL date, the type of bPI was not associ-
ated with the outcome of virological suppression (VL <
400 copies/ml) (Table 2).
Discussion
In this snapshot of African patients on second-line
ART, we report a high proportion of patients with
viral suppression on both boosted atazanavir and
boosted lopinavir containing regimens. Using different
VL cut-offs that is, < 1000 and < 400 copies/ml, the
proportions suppressed did not differ significantly be-
tween the two groups. However, further sensitivity
tests showed that the odds of being suppressed were
significantly different when a cutoff of < 75 copies/ml
was used (p = 003). However previous studies have
shown that a VL < 75 copies/ml is not predictive of
virological failure and therefore while patients on
ATV/r are more likely to achieve a VL < 75 copies/ml
this might not confer an advantage in terms of clin-
ical outcomes [21, 22]. This trend in favor of ATV/r
at lower VL cut-offs in the real-life setting could be
driven by the better tolerability that would drive bet-
ter adherence in those taking it compared to LPV/r.
Table 1 Patient characteristics at time of switch to second-line anti-retroviral regimen
Characteristic ATV/r LPV/r P value
Eligible 252 225
Included, n (%) 224 (88.8) 205 (91.1) 0.663
Sex, n (%)
Female 148 (66.1) 128 (62.4) 0.223
Male 76 (33.9) 77 (37.6)
Age (years), median (IQR) 37 (30–42) 36 (31–42) 0.792
Grouped BMI, Kg/m2, n (%)a
Under weight 15 (6.9) 21 (11.4) 0.305
Normal 137 (63.4) 111 (60.0)
Over weight 64 (29.6) 53 (28.7)
Missing 8 20
First-line drug, n (%)
NVP 144 (64.3) 132 (64.4) 0.982
EFV 80 (35.7) 73 (35.6)
CD4 count cell/μl, median (IQR) 118 (59–214) 102 (59–189) 0.088
Viral load Log 10 copies/ml at switch to second- line, median (IQR) 4.5 (3.8–4.9) 4.5 (3.2–5.1) 0.421
Duration (months) on first-line therapy, median (IQR) 56 (28–80) 46 (25–67) 0.025
Duration (months on second-line by time of viral load, median (IQR) 19 (21–25) 40 (32–52) < 0.001
NRTI drugs in second line, n (%)
3TC-TDF 191 (85.3) 154 (75.1) 0.741
3TC-AZT 29 (12.9) 48 (23.4)
3TC-ABC 4 (1.8) 3 (1.5)
aBMI was categorized as Underweight (< 18.5 Kg/m2), Normal (18.5–24.9 Kg/m2),
Over weight (≥25.0) Kg/m2
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This however warrants more studies to confirm our
observation [11].
Our findings are similar to findings in other studies. In
Georgia a study evaluated outcomes of patients on both
boosted atazanavir and boosted lopinavir containing reg-
imens in PI-naïve patients failing first-line ART and
multivariate analysis revealed that the type of bPI used
was not associated with the odds of suppression [23].
Similarly, the BMS 045 study was undertaken in patients
on boosted atazanavir and boosted lopinavir in resource
rich settings also showed no significant differences in
virological outcomes in the two groups. However, the
patients in the BMS study had previously received PI
regimens with some having PI mutations and resistance
testing was available to guide the choice of the nucleos(-
t)ides used in the PI regimen [24]. Both studies used a
cut-off of ≥400 copies/ml for virological failure. How-
ever, BMS also had further analyses using a cut-off of 50
copies/ml showing no difference in suppression rates be-
tween boosted atazanavir and lopinavir.
Boosted lopinavir has a higher genetic barrier than
boosted atazanavir [12]. However, genetic barrier alone
may not be a predictor of how a drug will perform. In
the 2-LADY study, though boosted darunavir has a
Table 2 Multivariate analysis by virological outcome (VL < 400 copies/ml)
Variable Adjusted OR (95% CI) P value
Sex
Female Reference .
Male 0.63 (0.29–1.34) 0.233
Second-line regimen group
ATV/r Reference .
LPV/r 0.46 (0.20–1.03) 0.060
Age at switch to second-line, per 5 year increase 0.91 (0.76–1.10) 0.332
CD4 count cell/μl, at switch to second-line 0.99 (0.99–1.00) 0.468
Time (months) on first-line therapy 1.00 (0.99–1.02) 0.701
Time (years) after switch to viral load date 1.27 (0.95–1.68) 0.103
Note: Adjusted for matching using propensity scores:
Fig. 2 Percentage suppression with different viral load cutoffs in patients by duration on second line therapy at time of viral load (standard ATV/r
versus LPV/r based second-line regimen)
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higher genetic barrier than boosted lopinavir, it did not
meet non-inferiority criteria in patients with a VL >
100,000 copies per ml [25]. Notably our findings show
that despite the lower genetic barrier, patients on
boosted atazanavir are achieving high levels of suppres-
sion similar to boosted lopinavir. This could be related
to its tolerability profile or ease of taking (less gastro-
intestinal side effects, less pills and once per day prepar-
ation) of the boosted atazanavir.
While our study is the first to the best of our know-
ledge to attempt to compare outcomes between the two
drugs when used in a resource-limited setting, it must
be emphasized that it is cross-sectional in nature. A
study with longitudinal follow up of viral loads would
have been less prone to survivor bias however viral load
monitoring was not available for routine care till Decem-
ber 2014 so there was no opportunity for this. The pop-
ulations differed in terms of their durations on
treatment though on stratifying the virological outcomes
by duration on second-line, there was still no significant
differences in the odds of being suppressed when on
either PI type. Patient accrual through death, loss to fol-
low up and transfer out for stable patients were similar
in both groups.
Another limitation of our study was that we were not
able to control for all possible predictors of the viro-
logical outcome at the multivariate stage such as viral
load at switch, opportunistic infections and adherence.
Whilst a randomized study as well data from cohorts
with longitudinal VL monitoring would provide the
strongest evidence on non-inferiority of atazanavir, we
find this observational data to be reassuring for the
increasingly large numbers of patients receiving generic
atazanavir in sub-Saharan Africa. In addition, since this
study involved patients who had been followed up prior
to ART switch without routine VLs, it is applicable to a
vast number of resource-limited settings that have low
coverage of VL monitoring.
Conclusion
Boosted atazanavir regimens had comparable virological
outcomes to boosted lopinavir regimens in patients fail-
ing first line therapy in settings where there has not
been routine viral load monitoring. There is also a trend
towards better suppression rates with boosted ATV/r
when lower cut-offs (vl < 75 copies/ml) are used. This
evidence supports the WHO recommendation of
boosted atazanavir as a component of second-line regi-
mens in developing countries.
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